The Anti-Hypertensive Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Anti-Hypertensive Drugs Market:
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
According to The Business Research Company’s Anti-Hypertensive Drugs Global Market Report 2024, The anti-hypertensive drugs market size has grown steadily in recent years. It will grow from $35.8 billion in 2023 to $36.7 billion in 2024 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to environmental and lifestyle influences, historical market competition, historical treatment preferences, economic conditions, historical global health trends.
The anti-hypertensive drugs market size is expected to see steady growth in the next few years. It will grow to $40.28 billion in 2028 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to cost-effectiveness and affordability, emerging therapeutic innovations, epidemiological trends, regulatory changes and approvals, aging population dynamics, healthcare policies and reimbursement changes. Major trends in the forecast period include therapeutic innovation, epidemiological shifts, regulatory landscape, healthcare policies, advancements in diagnosis and monitoring.
A sedentary lifestyle is a major driver of the growth of the anti-hypertensive drug market. Consumption of junk food, lack of proper healthy and balanced diet, and lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed with hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. Furthermore, in June 2021, according to the World Health Organization data 2021, a Switzerland-based Government agency responsible for international public health, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2410&type=smp
The anti-hypertensive drugs market covered in this report is segmented –
1) By Therapeutics: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators
2) By Disease Source: Primary Hypertension, Secondary Hypertension
3) By End Users: Hospitals, Clinics, Homecare
Major companies operating in the anti-hypertensive drugs market are focusing on innovating new products, such as Metoprolol Succinate Extended-Release Tablets, to provide a competitive edge in the market. Metoprolol Succinate Extended-Release Tablets are used as anti-hypertensive drugs for patients with hypertension. For instance, in June 2023, Granules India Limited, an Indian-based pharmaceutical manufacturing company, launched Metoprolol Succinate Extended-Release Tablets approved by the Food and Drug Administration (FDA), a US-based federal agency. Metoprolol Succinate Extended-Release Tablets are anti-hypertensive drugs designed for the treatment of hypertension in order to lower blood pressure. These tablets are available in varying strengths, including 25mg, 50mg, 100mg, and 200mg. This consists of beta-blockers that slow down the heart rate, reduce the workload on the heart, and lower blood pressure.
The anti-hypertensive drugs market report table of contents includes:
- Executive Summary
- Anti-Hypertensive Drugs Market Characteristics
- Anti-Hypertensive Drugs Market Trends And Strategies
- Anti-Hypertensive Drugs Market - Macro Economic Scenario
- Global Anti-Hypertensive Drugs Market Size and Growth
.
.
.
- Global Anti-Hypertensive Drugs Market Competitive Benchmarking
- Global Anti-Hypertensive Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In Anti-Hypertensive Drugs Market
- Anti-Hypertensive Drugs Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- fizer Inc.
- Johnson & Johnson Ltd.
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
A recent report published by TheBusinessResearchCompany on Anti-Hypertensive Drugs Market provides in-depth analysis of segments and sub-segments in the global as well as regional.The Anti-Hypertensive Drugs Global Market Report 2019 which provides strategists, marketers and senior management with the critical information they need to assess the global anti-hypertensive drugs market.
The report covers the anti-hypertensive drugs market’s segments- diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta blockers, alpha blockers, calcium channel blockers, renin inhibitors, vasodilators, primary hypertension, secondary hypertension, hospitals, clinics, and homecare.Anti-Hypertensive Drugs Global Market Report 2019 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 50+ geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It also compares the market’s historic and forecast growth.It covers all the regions, key developed countries and major emerging markets.
It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Of late, there has been a rise in use of combination therapies compared to monotherapy treatment.
TheBusinessResearchCompany published its Cardiovascular Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs market.
The report covers the cardiovascular drugs market’s segments- anti-hypertensive drugs, hypolipidemics, anti thrombotics, other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs).Explore Complete Report https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-reportCardiovascular Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2134=smpNOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin.
Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases.
Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.Purchase Report (Individual License at USD 4000.00) At: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2134Chapters from Table of Content:Chapter 1.
